OncoMatch/Clinical Trials/NCT05796973
Measuring Oncological Value of Exercise and Statin
Is NCT05796973 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Atorvastatin for prostate cancer.
Treatment: Atorvastatin — The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Breast Carcinoma
Renal Cell Carcinoma
Ovarian Cancer
Disease stage
Required: Stage III, IV
Metastatic disease required
Demographics
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05796973 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages